What are JAK inhibitor drugs?

JAK inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting Janus kinase (JAK) enzymes, particularly JAK1 and JAK2). 15 are currently marketed, with 20 more in clinical development.

What are the marketed JAK inhibitor drugs?

Marketed JAK inhibitor drugs include Rinvoq, Xeljanz, Xeljanz, Abrocitinib 200 mg, Abrocitinib tablet, Abrocitinib Suspension F1.

JAK inhibitor

15 marketed 10 in Phase 3 9 in Phase 2 1 in Phase 1

This page covers all JAK inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Janus kinase (JAK) enzymes, particularly JAK1 and JAK2, Janus kinase (JAK) enzymes, JAK1.

Targets

Janus kinase (JAK) enzymes, particularly JAK1 and JAK2 · Janus kinase (JAK) enzymes · JAK1 · JAK1, JAK3 · JAK pathway · Janus kinase (JAK) pathway · JAK1, JAK2, JAK3, and/or TYK2 · JAK1 and JAK2 · JAK1, JAK2, JAK3, TYK2 · JAK1, JAK3, JAK2

Marketed (15)

Rinvoq · AbbVie Inc. · Immunology · 5300
JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways.
Xeljanz · Pfizer · Immunology · 1800
Tofacitinib is a JAK inhibitor that prevents phosphorylation and activation of STATs.
Xeljanz · Pfizer · 1087
Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation.
Abrocitinib 200 mg · Pfizer · Immunology · 284
Abrocitinib tablet · Pfizer · 284
Abrocitinib Suspension F1 · Pfizer · Immunology · 284
Abrocitinib Suspension F6 · Pfizer · Immunology · 284
Abrocitinib 200 MG Oral Tablet · Pfizer · 284
Abrocitinib 200 MG Oral Tablet is a small molecule that targets the JAK1 protein.
Xeljanz · Pfizer · Immunology
Tofacitinib inhibits Janus kinase enzymes to prevent STAT phosphorylation and activation.
CP-690,550 · Pfizer · Immunology
CP-690,550 (tofacitinib) is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.
Chronic- PF-06480605 50 mg SC Q4W · Pfizer · Immunology
Pf-07293893 · Pfizer · Oncology
JAK Inhibitor · Fred Hutchinson Cancer Center · Oncology, Immunology
JAK inhibitors block Janus kinase enzymes, which are intracellular signaling proteins that transmit inflammatory and immune signals from cell surface receptors.
Tofacitinib tablet · Shanghai Zhongshan Hospital · Immunology
Tofacitinib inhibits Janus kinase (JAK) enzymes to suppress inflammatory cytokine signaling and reduce immune-mediated inflammation.
Induction- PF-06480605 150 mg SC Q4W · Pfizer · Immunology
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks.

Phase 3 pipeline (10)

high dose ruxolitinib · Beijing Friendship Hospital · Oncology, Immunology
Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in the signaling of various cytokines involved in inflammation and immune responses.
Delgocitinib cream · LEO Pharma · Dermatology / Immunology
Delgocitinib is a JAK inhibitor that suppresses inflammatory cytokine signaling in immune cells to reduce skin inflammation and itching in atopic dermatitis.
CP690,550 · Pfizer · Immunology
CP690,550 is a JAK inhibitor that selectively blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.
Placebo/CP-690,550 · Pfizer · Immunology
CP-690,550 is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory immune responses.
low dose ruxolitinib · Beijing Friendship Hospital · Oncology
Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK1 and JAK2 enzymes, which play a key role in signaling pathways involved in inflammation and immune responses.
CP-690,550 (tofacitinib) · Pfizer · Immunology
Tofacitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.
Upadacitinib (ABT-494) · AbbVie · Immunology
Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response.
Upadacitinib Oral Product · McMaster University · Immunology
Upadacitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a key role in the inflammatory response.
baricitinib treatment · University Hospital, Bordeaux · Immunology
Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of JAK enzymes, which play a role in inflammation.
Baricitinib Oral Tablet · Azienda Ospedaliero, Universitaria Pisana · Immunology
Baricitinib is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.

Phase 2 pipeline (9)

AN2728 Topical Ointment, 2% BID · Pfizer · Dermatology
AN2728 is a topical ointment that targets the Janus kinase (JAK) pathway to modulate inflammation.
AN2728 Topical Ointment, 0.5% BID · Pfizer · Dermatology
AN2728 is a topical ointment that targets the Janus kinase (JAK) pathway to modulate inflammation.
ATI-1777 · Aclaris Therapeutics, Inc. · Immunology
ATI-1777 is a small molecule inhibitor of the JAK1 and JAK2 enzymes.
ATI-50002 topical solution · Aclaris Therapeutics, Inc. · Dermatology
ATI-50002 topical solution is a small molecule that targets the Janus kinase (JAK) pathway.
CP-690,550 Ointment 2 · Pfizer · Immunology
CP-690,550 is a Janus kinase (JAK) inhibitor.
CP-690,550 Ointment 1 · Pfizer · Immunology
CP-690,550 is a Janus kinase (JAK) inhibitor.
ARQ-154 · Arcutis Biotherapeutics, Inc. · Dermatology
ARQ-154 is a topical Janus kinase (JAK) inhibitor.
Oral Fedratinib · Celgene · Oncology
JAK2 inhibitor
CGB-500 Ointment with 1% tofacitinib · CAGE Bio Inc. · Immunology
Tofacitinib is a Janus kinase (JAK) inhibitor that suppresses the activity of JAK enzymes, which play a key role in the signaling of cytokines involved in inflammation.

Phase 1 pipeline (1)

A: pacritinib · CTI BioPharma · Oncology
JAK2 inhibitor